TAIPEI, December 28, 2023 — REGiMMUNE Limited, a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for immune disorders and cancer, has announced promising Phase 2b clinical data. This study involves 48 patients who received RGI-2001 to prevent acute graft-versus-host disease (aGVHD). This Phase 2 study assesses the safety and efficacy of RGI-2001 in preventing aGVHD in patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The findings were presented at the 2024 Tandem Meeting in San Antonio, Texas, on February 22, 2024. ClinDatrix has provided the essential clinical services for this demanding clinical trial.
The Experience of Big. The Advantage of Value.
- About Us
- Services
- Clinical Trial Project Management
- Clinical Trial Investigator Meetings & Event Planning
- Clinical Trial Monitoring
- Clinical Trial Medical Monitor & Medical Safety
- Clinical Trial Data Management
- Clinical Trial Biostatistics
- Medical Writing Services
- Clinical Regulatory Affairs
- Quality Assurance for Clinical Trials
- Clinical Trials Consultant
- Therapeutic Areas
- Medical Devices
- Technology
- Global Affiliates
- Contact Us
Home » News & Events » ClinDatrix Client REGiMMUNE Successfully Announced Findings of Phase 2b Study at the 2024 Tandem Meeting